Company intelligence / Profile preview

Beijing Inno Medicine Co., Ltd.

Beijing, Beijing, Chinaen.innovmedicine.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Beijing Inno Medicine has developed a proprietary nano-drug targeted delivery platform with multiple patents. Its lead asset YN001—a first-in-class cardiovascular-targeted drug—has received IND approval from both the US FDA and China NMPA and entered Phase II clinical trials for coronary artery disease. The company also develops therapies for malignant glioma and rheumatoid arthritis. It operates GMP-compliant manufacturing facilities and aims to address unmet needs in cardiovascular, cerebrovascular, oncology, immune system diseases, among others.[2][3][6]

Therapeutic areas: OncologyCardiovascularRheumatology
Modalities: Small molecule drugs[3]siRNA[3]Contrast agents[3]Nano-drug targeted delivery platform (liposomal/nanoparticle-based)[6]
Industry: Biotech

Drug pipeline

2 assets

YN001

1 more asset in the full pipeline.

Beyond the preview

Go deeper on Beijing Inno Medicine Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Inno Medicine Co., Ltd..